Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines

References

1. ↵
   Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol 2003;250:1407–19

   CrossRefPubMedWeb of Science
2. ↵
   McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–27

   CrossRefPubMedWeb of Science
3. ↵
   Dalton CM, Brex PA, Miszkiel KA, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003;53:673–76

   CrossRefPubMedWeb of Science
4. Miller DH, Filippi M, Fazekas F, et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol 2004;56:273–78

   CrossRefPubMedWeb of Science
5. ↵
   Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27–30

   Abstract/FREE Full Text
6. ↵
   Herndon RM, Coyle PK, Murray TJ, et al. Report of the consensus panel on the new international panel guidelines for diagnosis of MS. Int J MS Care 2002;4:170–73
7. ↵
   Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602–11

   Abstract/FREE Full Text
8. ↵
   Kinkel RP, Rudick RA. Section 13. The nervous system. Multiple sclerosis. In: Rakel RE, Bope, ET, eds. 2002 Conn’s current therapy. Philadelphia: WB Saunders;2002 ,922–37
9. ↵
   Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47–53

   CrossRefPubMedWeb of Science
10. ↵
    CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59:998–1005

    Abstract/FREE Full Text
11. ↵
    Bot JC, Barkhof F, Lycklama A, et al. Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology 2002;223:46–56

    CrossRefPubMedWeb of Science
12. ↵
    Lycklama G, Thompson A, Filippi M, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2003;2:555–62

    CrossRefPubMedWeb of Science
13. ↵
    Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 2003;23:133–46

    CrossRefPubMedWeb of Science
14. ↵
    Freedman MS, Patry DG, Grand’Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157–68.

    PubMedWeb of Science
15. ↵
    Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548–55

    CrossRefPubMedWeb of Science
16. ↵
    van Walderveen MA, Barkhof F, Pouwels PJ, et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46:79–87

    CrossRefPubMedWeb of Science
17. ↵
    Richert ND. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.”; Neurology 2002;58:1440–41; author reply 1441–42

    FREE Full Text
18. ↵
    Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412–20

    Abstract/FREE Full Text
19. ↵
    Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–64

    CrossRefPubMedWeb of Science
20. ↵
    Tas MW, Barkhof F, van Walderveen MAA, et al. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259–64

    Abstract/FREE Full Text
21. ↵
    Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 997;120:2059–69
22. ↵
    Silver NC, Good CD, Sormani MP, et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 2001;248:215–24

    CrossRefPubMedWeb of Science
23. ↵
    Cotton F, Weiner HL, Jolesz FA, et al. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46

    Abstract/FREE Full Text
24. ↵
    Filippi M, the White Matter Study Group. Magnetic resonance techniques for the in-vivo assessment of multiple sclerosis pathology: consensus report of the White Matter Study Group. J Mag Reson Imaging 2005;21:669–75

    CrossRefPubMedWeb of Science
25. ↵
    Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271–78

    CrossRefPubMedWeb of Science
26. ↵
    Lee DH, Vellet AD, Eliasziw M, et al. MR imaging field strength: prospective evaluation of the diagnostic accuracy of MR for diagnosis of multiple sclerosis at 0.5 and 1.5 T. Radiology 1995;194:257–62

    PubMedWeb of Science
27. Schima W, Wimberger D, Schneider B, et al. The importance of magnetic field strength in the MR diagnosis of multiple sclerosis: a comparison of 0.5 and 1.5 T. Rofo 1993;158:368–71

    PubMed
28. ↵
    Filippi M, van Waesberghe JH, Horsfield MA, et al. Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. Neurology 1997;49:371–77

    Abstract/FREE Full Text
29. ↵
    Bot JC, Barkhof F, Lycklama A, et al. Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. Eur Radiol 2000;10:753–58

    CrossRefPubMed
30. Campi A, Pontesilli S, Gerevini S, et al. Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord. Neuroradiology 200;42:669–75
31. Dietemann JL, Thibaut-Menard A, Warter JM, et al. MRI in multiple sclerosis of the spinal cord: evaluation of fast short-tau inversion-recovery and spin-echo sequences. Neuroradiology 2000;42:810–13

    PubMed
32. ↵
    Rocca MA, Mastronardo G, Horsfield MA, et al. Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol 1999;20:1710–16

    Abstract/FREE Full Text
33. ↵
    Palmer S, Bradley WG, Chen D-Y, et al. Subcallosal striations: early findings of multiple sclerosis on sagittal, thin-section, fast FLAIR MR images. Radiology 1999;210:149–53

    PubMedWeb of Science
34. ↵
    Filippi M, Marciano N, Capra R, et al. The effect of imprecise repositioning on lesion volume measurements in patients with multiple sclerosis. Neurology 1997;49:274–46

    Abstract/FREE Full Text
35. ↵
    Rovaris M, Rocca MA, Capra R, et al. A comparison between the sensitivities of 3-mm and 5-mm thick serial brain MRI for detecting lesion volume changes in patients with multiple sclerosis. J Neuroimaging 1998;8:144–47

    CrossRefPubMedWeb of Science
36. ↵
    Mathews VP, Caldemeyer KS, Lowe MJ, et al. Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology 1999;211:257–63

    PubMed
37. ↵
    Wolinsky JS. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci 2003;206:145–52

    CrossRefPubMedWeb of Science
38. ↵
    Stevenson VL, Parker GJ, Barker GJ, et al. Variations in T1 and T2 relaxation times of normal appearing white matter and lesions in multiple sclerosis. J Neurol Sci 2000;178:81–87

    CrossRefPubMedWeb of Science
39. ↵
    Hahn CD, Shroff MM, Blaser SI, et al. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology 2004;62:806–08

    Abstract/FREE Full Text